Project Grant R01CA296394
Award Date
12/10/24
Completion Date
11/30/29
Dollars Obligated
$488K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $590,960.00 in funding to the Beckman Research Institute of the City of Hope to conduct research aimed at improving the understanding and treatment of acute myeloid leukemia (AML). The key objectives of the project are to: 1) Quantify the dynamics of leukemia potential driven by different oncogenic signals in murine models, 2) Evaluate the effects of treatment on leukemia...
The National Cancer Institute (NCI), under the Cancer Treatment Research (CFDA 93.395) federal grant program, awarded a $734,435 Project Grant to the Beckman Research Institute of the City of Hope on March 10, 2025. The grant supports research to overcome resistance to BH3 mimetic drugs, a targeted therapy for acute myeloid leukemia (AML), by inhibiting the ADSS2 enzyme involved in AMP biosynthesis. The research aims to: 1) Correlate ADSS2 levels with BH3 mimetic responsiveness in primary AML...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), is supporting research at Case Western Reserve University (CWRU) to investigate mechanisms of resistance to proteasome inhibitors in acute myeloid leukemia (AML). The $491,357 award, granted on March 15, 2025, aims to establish a mechanistic understanding of how activation of the mTOR pathway can sensitize AML cells to proteasome inhibitor therapy. The research will...
The National Cancer Institute (NCI) awarded a $237,023 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai. The 3-year award (3/1/2025 - 2/29/2028) will fund the development and optimization of a scalable, high-throughput single-cell method (SHARE-ME-SEQ) to simultaneously profile gene expression, chromatin accessibility, and DNA methylation in acute myeloid leukemia (AML) samples. Researchers will apply this technology to analyze bone marrow...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
This Project Grant award of $458,698.00 was provided by the National Cancer Institute (NCI) under the federal Cancer Biology Research program (CFDA 93.396). The award, effective March 10, 2025 through February 28, 2030, supports research to identify novel genes and mechanisms underlying therapy resistance and relapse in acute myeloid leukemia (AML). The research aims to functionally validate candidate genes from prior single-cell RNA sequencing and CRISPR screens in order to better understand...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.396 - Cancer Biology Research) totaling $721,723 to the Beckman Research Institute of the City of Hope in Duarte, CA. The grant funding period runs from December 16, 2024 to November 30, 2029. The project aims to determine the role of the MGA/MYC/NME1 regulatory axis in driving the transition from chronic lymphocytic leukemia (CLL) to the more aggressive Richter's transformation (RT). The research will investigate how this...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $542,663 to The University of Texas MD Anderson Cancer Center to conduct preclinical research on using BRG1/BRM antagonists to treat acute myeloid leukemia (AML) with MLL rearrangement or mutant NPM1. The research aims to determine the efficacy of BRG1/BRM inhibitor and degrader compounds, evaluate combination regimens with these agents, and overcome resistance to menin inhibitors...
This $878,400 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Biology Research program (CFDA 93.396) will fund research characterizing vitamin B6 pathway dependency in acute myeloid leukemia (AML) at Cold Spring Harbor Laboratory from January 2023 through December 2027. The research aims to further the understanding of the underlying mechanisms of AML by studying abnormal vitamin pathways and metabolic programming...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $768,437 to the Sanford Burnham Prebys Medical Discovery Institute to conduct research aimed at identifying chemical compounds that inhibit the chromatin reader SGF29, which regulates the transcription of oncogenes in acute myeloid leukemia (AML). The research project will implement high-throughput screening assays developed by the institute to screen chemical libraries and identify...